Perspectives
Engaging Medicare members improves adherence, can lead to higher Star ratings
November 15, 2015When members don’t take their medicine as prescribed, it can lead to increased hospitalizations and poor health outcomes. For Medicare plan sponsors, nonadherence drives up unnecessary health care costs. And the financial impact doesn’t end there.
Adherence measures account for 28 percent of a Prescription Drug Plan’s (PDP) Star ratings. Encouraging adherence and achieving a high Star rating are top priorities, and for good reason. In 2015, plans with ratings of less than four stars will lose out on an estimated $3.47 billion in bonus payments.1
What we studied
The Centers for Medicare and Medicaid Services requires PDP sponsors to provide Medication Therapy Management (MTM) programs to help optimize health outcomes. To learn how MTM programs impact adherence — and eventually Star ratings — our team of researchers analyzed pharmacy claims data for 1.2 million Medicare members. We compared adherence between qualified members who engaged in MTM* vs. those who did not within the three drug adherence Star ratings categories: diabetes, statins and renin angiotensin system (RAS) antagonists).
What we learned
When analyzing the data, Prime found significant correlation with engagement in an MTM program and adherence. The proportion of adherent members who participated in MTM were:
- 40 percent higher for oral diabetes medicine
- 20 percent higher for statins
- 20 percent higher for RAS antagonists
Why we did this study
Understanding how MTM impacts adherence is an important part of PDP sponsors’ Star ratings strategy. Our findings validate the importance of promoting MTM programs and making it easy for members to participate. Focusing on MTM engagement not only sets the stage for financial success — it helps ensure that members are getting the medicine they need to feel better and live well.
Related news
Perspectives
May 1, 2024
Prime Therapeutics releases new clinical insights report, “Weight management: A holistic journey”
Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss
Perspectives
April 30, 2024
AMCP 2024: Behind the GLP-1 Spotlight Session with Ben Urick
Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting
Perspectives
April 30, 2024
Quarterly Drug Pipeline
Clinical insights and competitive intelligence on anticipated drugs in development